Who owns Biodexa Pharmaceuticals Plc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Institutional ownership of BDRX from SEC Form 13F filings across 5 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 5 institutions disclosed 1,752 shares of Biodexa Pharmaceuticals Plc worth $4,946 — about 0% of shares outstanding; the largest disclosed holder is GAMMA Investing LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
5
13F holders
$4,946
value, 2026 filers
0%
of shares outstanding (1,752 sh)
4
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of BDRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | GAMMA Investing LLCNEW | 1,203 | $3,501 | 0.0% | 0% | new |
| 2 | Allied Private Wealth LLCNEW | 489 | $1,271 | 0.0% | 0% | new |
| 3 | SBI Securities Co., Ltd. | 29 | $84 | 0.0% | 0% | -80.8% |
| 4 | UBS Group AGNEW | 25 | $73 | 0.0% | 0% | new |
| 5 | Hilton Head Capital Partners, LLCNEW | 6 | $17 | 0.0% | 0% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.